Medicine
Tecentriq 840 mg/14 mL injection
Tecentriq 840 mg/14 mL injection is a prescription medicine containing Atezolizumab for intravenous use, marketed by Genentech, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original…
Key facts
- Active ingredient (INN)
- Atezolizumab
- Brand
- Tecentriq
- Strength
- 840 mg/14 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 14 mL
- Marketing authorisation holder
- Genentech
- Manufacturer
- Genentech
- Origin register
- US FDA, United States
- Storage
- Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FF05 Atezolizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 March 2019
- Identifiers
- RxCUI 1792780, 1792785, 2119695 +1DailyMed set ID 6fa682c9-a312-4932-9831-f286908660eeNDC 50242-918Application BLA761034
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 14 mL in 1 vial, single-use | 50242-918-01 | Genentech | 8 March 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Atezolizumab
Clinical summary
Atezolizumab is a programmed death receptor-1 blocking antibody indicated for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. MedsAcross supplies Atezolizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AtezolizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TECENTRIQ prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- Tecentriq: European public assessment report (EPAR) · European Medicines Agency
Need Tecentriq 840 mg/14 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.